220 related articles for article (PubMed ID: 32447585)
1. Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç I; Öztürk E; Varan A; Akyüz C
Jpn J Ophthalmol; 2020 Jul; 64(4):351-358. PubMed ID: 32447585
[TBL] [Abstract][Full Text] [Related]
2. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
3. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
5. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.
Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL
Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478
[TBL] [Abstract][Full Text] [Related]
6. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
7. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
[TBL] [Abstract][Full Text] [Related]
9. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
Xue K; Ren H; Meng F; Zhang R; Qian J
BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
[TBL] [Abstract][Full Text] [Related]
10. Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.
Karl MD; Francis JH; Iyer S; Marr B; Abramson DH
J Pediatr Ophthalmol Strabismus; 2017 May; 54(3):185-190. PubMed ID: 28092395
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç İ; Varan A; Akyüz C
Eur J Ophthalmol; 2017 Jun; 27(4):423-427. PubMed ID: 28106239
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma.
Rao R; Honavar SG; Sharma V; Reddy VAP
Br J Ophthalmol; 2018 Apr; 102(4):490-495. PubMed ID: 28844050
[TBL] [Abstract][Full Text] [Related]
14. Is intravitreal topotecan toxic to retinal function?
Nadelmann J; Francis JH; Brodie SE; Muca E; Abramson DH
Br J Ophthalmol; 2021 Jul; 105(7):1016-1018. PubMed ID: 32665221
[TBL] [Abstract][Full Text] [Related]
15. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds.
Lee JH; Han JW; Hahn SM; Lyu CJ; Kim DJ; Lee SC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):391-4. PubMed ID: 26511530
[TBL] [Abstract][Full Text] [Related]
16. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.
Riazi-Esfahani H; Masoomian B; Khodabandeh A; Amini A; Taghizadeh S; Boujabadi L; Sharifkashani S; Shields CL; Ghassemi F
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1167-1175. PubMed ID: 36401651
[TBL] [Abstract][Full Text] [Related]
17. Pathological findings in enucleated eyes after intravitreal melphalan injection.
Ghassemi F; Amoli FA
Int Ophthalmol; 2014 Jun; 34(3):533-40. PubMed ID: 24043335
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL
Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal chemotherapy provides control for massive vitreous seeding from retinoblastoma.
Lawson BM; Saktanasate J; Say EA; Shields CL
J Pediatr Ophthalmol Strabismus; 2014 Dec; 51 Online():e92-4. PubMed ID: 25490242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
